Literature DB >> 19543223

The 'big pharma' dilemma: develop new drugs or promote existing ones?

Dan Weiss1, Prasad Naik, Ram Weiss.   

Abstract

Mesh：

Year:  2009        PMID： 19543223     DOI： 10.1038/nrd2923

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  6 in total

1.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

2.  The NIH budget and the future of biomedical research.

Authors:  Joseph Loscalzo
Journal:  N Engl J Med       Date:  2006-04-20       Impact factor: 91.245

3.  Drug discovery in jeopardy.

Authors:  Pedro Cuatrecasas
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

Review 4.  Helping science to succeed: improving processes in R&D.

Authors:  Andreas Sewing; Toby Winchester; Pauline Carnell; David Hampton; Wilma Keighley
Journal:  Drug Discov Today       Date:  2008-03-05       Impact factor: 7.851

5.  A decade of direct-to-consumer advertising of prescription drugs.

Authors:  Julie M Donohue; Marisa Cevasco; Meredith B Rosenthal
Journal:  N Engl J Med       Date:  2007-08-16       Impact factor: 91.245

6.  The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States.

Authors:  Marc-André Gagnon; Joel Lexchin
Journal:  PLoS Med       Date:  2008-01-03       Impact factor: 11.069
  6 in total
  1 in total

1.  Pension and state funds dominating biomedical R&D investment: fiduciary duty and public health.

Authors:  Slavek Roller
Journal:  Global Health       Date:  2019-11-06       Impact factor: 4.185
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.